FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890830942> ?p ?o ?g. }

• W2890830942 endingPage "213" @default.
• W2890830942 startingPage "205" @default.
• W2890830942 abstract "Synucleinopathies including Parkinson's disease (PD) and Dementia with Lewy bodies (DLB) are characterized by the accumulation of abnormal α-synuclein in intraneuronal inclusions, named Lewy bodies. Mutations in GBA1, the gene encoding the lysosomal hydrolase glucocerebrosidase, have been identified as the most common genetic risk factor for PD and DLB. However, despite extensive research, the mechanism by which glucocerebrosidase dysfunction increases the risk for PD or DLB still remains elusive. In our study we expand the toolbox for PD-DLB post-mortem studies by introducing new quantitative biochemical assays for glucocerebrosidase and α-synuclein. Applying causal modelling, we determine how these parameters are interrelated and ultimately impact disease manifestation. We developed quantitative immuno-based assays for glucocerebrosidase and α-synuclein (total and phosphorylated at Serine 129) protein levels, as well as a liquid chromatography-mass spectrometry method for the detection of the glucocerebrosidase lipid substrate glucosylsphingosine. These assays were applied on tissue samples from frontal cortex, putamen and substantia nigra of PD (n = 15) and DLB (n = 15) patients and age-matched non-demented controls (n = 15). Our results confirm elevated p-129 over total α-synuclein levels in the insoluble fraction of PD and DLB post-mortem brain tissue and we found significantly increased α-synuclein levels in the soluble fractions in PD and DLB. Furthermore, we identified an inverse correlation between reduced glucocerebrosidase enzyme activity and protein levels with increased glucosylsphingosine levels. In the substantia nigra, a brain region particularly vulnerable in Parkinson's disease, we found a significant correlation between glucocerebrosidase protein reduction and increased p129/total α-synuclein ratios. We assessed the direction and strength of the interrelation between all measured parameters by confirmatory path analysis. Interestingly, we found that glucocerebrosidase dysfunction impacts the PD-DLB status by increasing α-synuclein ratios in the substantia nigra, which was partly mediated by increasing glucosylsphingosine levels. In conclusion, we show that the introduced immuno-based assays enable the quantitative assessment of glucocerebrosidase and α-synuclein parameters in post-mortem brain. In the substantia nigra, reduced glucocerebrosidase levels contribute to the increase in α-synuclein levels and to PD-DLB disease manifestation partly by increasing its glycolipid substrate glucosylsphingosine. This interrelation between glucocerebrosidase, glucosylsphingosine and α-synuclein parameters supports the hypothesis that glucocerebrosidase acts as a modulator of PD-DLB." @default.
• W2890830942 created "2018-09-27" @default.
• W2890830942 creator A5011401160 @default.
• W2890830942 creator A5040534974 @default.
• W2890830942 creator A5049461821 @default.
• W2890830942 creator A5056277100 @default.
• W2890830942 creator A5061967495 @default.
• W2890830942 creator A5071946210 @default.
• W2890830942 creator A5074411763 @default.
• W2890830942 creator A5078865376 @default.
• W2890830942 creator A5083194930 @default.
• W2890830942 date "2019-01-01" @default.
• W2890830942 modified "2023-10-16" @default.
• W2890830942 title "Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels" @default.
• W2890830942 cites W1496790952 @default.
• W2890830942 cites W1527671059 @default.
• W2890830942 cites W1542222030 @default.
• W2890830942 cites W1874451973 @default.
• W2890830942 cites W1965095016 @default.
• W2890830942 cites W1972665983 @default.
• W2890830942 cites W1973738022 @default.
• W2890830942 cites W1975932268 @default.
• W2890830942 cites W1986216002 @default.
• W2890830942 cites W1986341243 @default.
• W2890830942 cites W1991087658 @default.
• W2890830942 cites W1996637092 @default.
• W2890830942 cites W2007820455 @default.
• W2890830942 cites W2009500387 @default.
• W2890830942 cites W2027334892 @default.
• W2890830942 cites W2028072328 @default.
• W2890830942 cites W2028806152 @default.
• W2890830942 cites W2031365272 @default.
• W2890830942 cites W2036110753 @default.
• W2890830942 cites W2055310246 @default.
• W2890830942 cites W2055445325 @default.
• W2890830942 cites W2057979657 @default.
• W2890830942 cites W2063754694 @default.
• W2890830942 cites W2073449985 @default.
• W2890830942 cites W2076844276 @default.
• W2890830942 cites W2079994150 @default.
• W2890830942 cites W2085022353 @default.
• W2890830942 cites W2087554951 @default.
• W2890830942 cites W2087968969 @default.
• W2890830942 cites W2093171209 @default.
• W2890830942 cites W2096739914 @default.
• W2890830942 cites W2108865709 @default.
• W2890830942 cites W2120668700 @default.
• W2890830942 cites W2123378289 @default.
• W2890830942 cites W2123431154 @default.
• W2890830942 cites W2124663723 @default.
• W2890830942 cites W2137300912 @default.
• W2890830942 cites W2144140825 @default.
• W2890830942 cites W2149584682 @default.
• W2890830942 cites W2150656456 @default.
• W2890830942 cites W2158745133 @default.
• W2890830942 cites W2168784140 @default.
• W2890830942 cites W2170281382 @default.
• W2890830942 cites W2337871602 @default.
• W2890830942 cites W2591558604 @default.
• W2890830942 cites W2746979715 @default.
• W2890830942 cites W2807303222 @default.
• W2890830942 doi "https://doi.org/10.1016/j.nbd.2018.09.015" @default.
• W2890830942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30236861" @default.
• W2890830942 hasPublicationYear "2019" @default.
• W2890830942 type Work @default.
• W2890830942 sameAs 2890830942 @default.
• W2890830942 citedByCount "39" @default.
• W2890830942 countsByYear W28908309422019 @default.
• W2890830942 countsByYear W28908309422020 @default.
• W2890830942 countsByYear W28908309422021 @default.
• W2890830942 countsByYear W28908309422022 @default.
• W2890830942 countsByYear W28908309422023 @default.
• W2890830942 crossrefType "journal-article" @default.
• W2890830942 hasAuthorship W2890830942A5011401160 @default.
• W2890830942 hasAuthorship W2890830942A5040534974 @default.
• W2890830942 hasAuthorship W2890830942A5049461821 @default.
• W2890830942 hasAuthorship W2890830942A5056277100 @default.
• W2890830942 hasAuthorship W2890830942A5061967495 @default.
• W2890830942 hasAuthorship W2890830942A5071946210 @default.
• W2890830942 hasAuthorship W2890830942A5074411763 @default.
• W2890830942 hasAuthorship W2890830942A5078865376 @default.
• W2890830942 hasAuthorship W2890830942A5083194930 @default.
• W2890830942 hasConcept C126322002 @default.
• W2890830942 hasConcept C185592680 @default.
• W2890830942 hasConcept C2776925932 @default.
• W2890830942 hasConcept C2777440831 @default.
• W2890830942 hasConcept C2778548049 @default.
• W2890830942 hasConcept C2779097696 @default.
• W2890830942 hasConcept C2779134260 @default.
• W2890830942 hasConcept C2779483572 @default.
• W2890830942 hasConcept C2779714222 @default.
• W2890830942 hasConcept C2779734285 @default.
• W2890830942 hasConcept C2780674200 @default.
• W2890830942 hasConcept C2780938664 @default.
• W2890830942 hasConcept C2781449126 @default.
• W2890830942 hasConcept C71924100 @default.
• W2890830942 hasConceptScore W2890830942C126322002 @default.
• W2890830942 hasConceptScore W2890830942C185592680 @default.

• next